This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundVericiguata novel oral soluble guanylate cyclase stimulatorwas developed for the treatment of chronic heartfailure (HF). We matched 75 external control patients for this purpose.
This secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With HeartFailure (FINEARTS-HF) randomized clinical trial evaluates the effect of finerenone on outpatient worsening heartfailure events requiring oral diuretic intensification among patients with heartfailure with mildly reduced or (..)
Breakdown of the study population by worsening heartfailure (WHF) event proportions (oral diuretic intensification or heartfailure [HF] hospitalization) and KaplanMeier curve of all-cause mortality after WHF event shown, relative to a patient group that did not have any WHF events.
Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heartfailure , a leading cause of hospitalization and death. hospitals from emergency rooms.
Earlier research showed that primary care clinicians using AI-ECG tools identified more unknown cases of a weak heart pump, also called low ejection fraction, than without AI. New study findings suggest that this type of screening is also cost-effective in the long term, especially in outpatient settings.
CMS has reviewed the CardiAMP HeartFailure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP HeartFailure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
milla1cf Tue, 05/28/2024 - 07:00 May 28, 2024 — Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with heartfailure, according to research presented at HeartFailure 2024 , a scientific congress of the European Society of Cardiology (ESC).
This proof-of-principle study investigates the association between tissue sodium content, assessed by MRI, and HF-related baseline parameters in an outpatient cohort of patients with chronic heartfailure, including those with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), and preserved ejection fraction (HFpEF).Methods
Background The obesity occurrence has achieved epidemic levels worldwide and several studies indicate a paradoxical similarity among obesity and the prognosis in heartfailure (HF). Methods We analyzed 1,556 medical records from the HF outpatient clinic of a quaternary hospital and 242 were selected according to the criteria.
The clinical role and educational preparation of heartfailure nurses across Europe. HF, heartfailure; HFN, heartfailure nurse; MDT, multidisciplinary team. Most nurses, 78% ( n = 395) worked within a hospital outpatient setting, and 51% ( n = 431) had access to a specialized HF multidisciplinary team.
The goal of the FRESH-UP trial was to assess the safety and effect of lifestyle advice of a liberal vs. a restrictive fluid regimen in patients with chronic HF in an outpatient setting.
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heartfailure : heartfailure with reduced ejection fraction (HFrEF) and heartfailure with preserved ejection fraction (HFpEF).
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heartfailure : heartfailure with reduced ejection fraction (HFrEF) and heartfailure with preserved ejection fraction (HFpEF).
Patients with heartfailure (HF) who have worsening HF symptoms that require intensification of oral diuretics in the outpatient setting are common and associated with a poor prognosis, and finerenone reduced the need for intensifying diuretics.
Conclusion Patients with high levels of troponin, or NT-proBNP, or cystatin C who develop WHF despite being treated with a loop diuretic, need novel therapies for WHF.
Earlier research showed that primary care clinicians using AI-ECG tools identified more unknown cases of a weak heart pump, also called low ejection fraction, than without AI.
However, researchers said the drug may be helpful in reducing heartfailure risks, including hospitalization, following a heart attack. All secondary endpoints related specifically to heartfailure outcomes were significantly reduced among patients who received empagliflozin.
Among patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), vutrisiran reduced the risk of outpatient worsening heartfailure (HF) – which was itself associated with a 2.6-fold fold increased risk of all-cause mortality and cardiovascular events.
While composite of death and heartfailure hospitalizations was not significantly reduced, empagliflozin may help reduce heartfailure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,
AimsTo assess the barriers to guideline-directed medical therapy (GDMT) use in heartfailure (HF), diagnostic workup and general knowledge about HF among physicians in Sweden.MethodsA survey about the management of HF was sent to 828 Swedish physicians including general practitioners (GPs) and specialists during 2021–2022.
Aims Identifying clinical and echocardiographic parameters associated with improvement in systolic function in outpatients with heartfailure with reduced ejection fraction (HFrEF) could lead to more targeted treatment improving systolic function and outcome. Beta-coefficients (β-coef) are standardised. to 7.51, p=0.006).
Heartfailure with preserved ejection fraction (HFpEF) is a common concern in the medical field due to its prevalence in an ageing western population. HFpEF is associated with significant morbidity and mortality not dissimilar to heartfailure (HF) with reduced ejection fraction.
Publication date: Available online 1 April 2025 Source: The American Journal of Cardiology Author(s): Hubert B. Haywood, Lisa A. Kaltenbach, Uchechukwu Ikeaba, Gregg C. Fonarow, Karen Chiswell, Veraprapas Kittipibul, Muhammad Shahzeb Khan, Megha Gupta, Best Uchehara, Bradley G. Hammill, Javed Butler, Adrian F. Hernandez, G.
Introduction:Enhanced External Counterpulsation (EECP) is a noninvasive outpatient therapy designed to improve arterial health, cardiac efficiency, and coronary collateral formation by applying sequential external pressure aligned with the patient’s cardiac cycle.
Abstract Aims Fluid accumulation is associated with poor outcomes in patients with heartfailure (HF). After acute HF, HF nurses provide home care suggestions based on oedema status assessed at outpatient clinics. However, the pattern of serial oedema changes and their associations with patient outcomes are unknown.
Abstract Diagnosing heartfailure is often difficult due to the non-specific nature of symptoms, which can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heartfailure. Use of this acronym would enable the early diagnosis of heartfailure.
Diagrammatic illustration of trends of incident heartfailure diagnosis and diagnostic testing in the US from 2016 to 2019 stratified by inpatient and outpatient setting. However, real-world utilization of these diagnostic tests in the US is not known. A total of 124 126 patients were included.
(MedPage Today) -- For patients with chronic heartfailure (HF) who have persistent congestion despite high doses of oral loop diuretics, the right way to intensify diuretics in the outpatient setting may be narrowed, based on a small randomized.
Introduction This study aimed to evaluate the use and dose of loop diuretics (LDs) across the entire ejection fraction (EF) spectrum in a large, ‘real-world’ cohort of chronic heartfailure (HF) patients. Data regarding daily diuretic dose were stratified by furosemide dose equivalent (FDE)>80 mg or ≤80 mg.
The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave. Canada, Israel, Australia and New Zealand. HF affects 7 million people in the U.S,
Background: The heartfailure (HF) virtual consultation (VC) is an eHealth tool for delivery of peer-to-peer specialist advice to general practitioners (GPs) to discuss HF diagnosis/management. This may facilitate early diagnosis and management of suspected HF in the current era of long outpatient waiting times.
Aims We investigated the incremental advantage in terms of N-terminal pro-B-type natriuretic peptide (NT-proBNP) reduction in patients affected by heartfailure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan (S/V) and mineralocorticoid receptor antagonists (MRA) versus patients treated with S/V only.
Introduction The diagnostic and therapeutic arsenal for heartfailure with preserved ejection (HFpEF) has expanded. With novel therapies (eg, sodium-glucose co-transporter 2 inhibitors) and firmer recommendations to optimise non-cardiac comorbidities, it is unclear if outpatient HFpEF models can adequately deliver this.
Introduction:European, American and UK guidelines all endorse the prescription of the 'four pillars' of treatment (ACE/ARBs, b-blockers, MRAs and SGLT2 inhibitors) for heartfailure with reduced LV systolic function (HFrEF). Many doctors believe that it is difficult to initiate and maintain patients on all these medications.
Introduction:Chronic HeartFailure (HF) is a clinical syndrome that as a consequence of the compensatory mechanisms to maintain an adequate level of perfusion, causes dyspnea, peripheral edema, fatigue, lack of appetite, changes in body weight, cachexia, sarcopenia, among others.
Abstract Aims Early identification and management of worsening heartfailure (HF) is necessary to prevent disease progression and hospitalizations. Abstract Aims Early identification and management of worsening heartfailure (HF) is necessary to prevent disease progression and hospitalizations.
Permanent pacer placement Later, a biventricular pacer was placed for " Cardiac Resynchronization Therapy (CRT) " (This is indicated for patients with LBBB and QRS duration > 130 ms and heartfailure and vastly improves heartfailure). See Dr. Karim's further thoughts on this below.
A novel quality improvement (QI) initiative for guideline-directed medical therapy (GDMT) utilization increased angiotensin receptor-neprilysin inhibitor (ARNI) and mineralocorticoid receptor antagonist (MRA) prescriptions in outpatients with heartfailure with reduced ejection fraction (HFrEF,) according to an implementation perspective paper published (..)
Aims Heartfailure (HF) is associated with comorbidities which independently influence treatment response and outcomes. Outcome measures were (1) all-cause hospitalisations, (2) outpatient clinic attendances and (3) cost. Results 334 patients (mean age 72.5±11 ±4 months.
Similar findings were obtained when allcause death was considered as the end point.ConclusionsIn patients with chronic heartfailure and left ventricular ejection fraction <50%, TAPSE, and RVFAC are more accurate than S in predicting the risk of cardiac and allcause death.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content